| scholarly article | Q13442814 |
| P50 | author | Roger S McIntyre | Q88039086 |
| P2093 | author name string | Jeanette M Jerrell | |
| Avnish Tripathi | |||
| P2860 | cites work | National trends in the outpatient diagnosis and treatment of bipolar disorder in youth | Q28244462 |
| The impact of substance abuse on the course of bipolar disorder | Q29306635 | ||
| The use of administrative data to assess quality of care for bipolar disorder in a large staff model HMO. | Q30587195 | ||
| Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). | Q30925648 | ||
| Health and self-care practices of persons with schizophrenia | Q33664483 | ||
| Children with schizophrenia: clinical picture and pharmacological treatment. | Q33999778 | ||
| Tolerability profile of atypical antipsychotics in children and adolescents | Q34481346 | ||
| The effect of antidepressants on lipid homeostasis: a cardiac safety concern? | Q34538100 | ||
| Effects of psychotropic medications on the pediatric electrocardiogram and recommendations for monitoring | Q34618043 | ||
| “Dopamine-Dependent” Side Effects of Selective Serotonin Reuptake Inhibitors | Q56700907 | ||
| Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania | Q79470954 | ||
| Increased risk of hypertension in patients with bipolar disorder and patients with anxiety compared to background population and patients with schizophrenia | Q79731969 | ||
| Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization | Q80000044 | ||
| Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods | Q80713523 | ||
| Considering wellness in managing patients with bipolar disorder | Q81489929 | ||
| Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents | Q82222497 | ||
| Overweight and obesity in bipolar disorders | Q82729258 | ||
| Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study | Q83294329 | ||
| Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. | Q34735182 | ||
| Neuroleptic malignant syndrome. Recognition, prevention and management | Q34749651 | ||
| Which comes first: atypical antipsychotic treatment or cardiometabolic risk? | Q34932314 | ||
| Pharmacoeconomic implications of adverse effects during antipsychotic drug therapy. | Q35010617 | ||
| Medicaid expenditures on behavioral health care | Q35056204 | ||
| Pharmacological treatment of adolescent major depression | Q35772743 | ||
| Side effects of atypical antipsychotic drugs | Q35849629 | ||
| Comorbidity in bipolar disorder: a framework for rational treatment selection | Q35859860 | ||
| Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? | Q35867252 | ||
| Association between obesity and psychiatric disorders in the US adult population | Q35880425 | ||
| Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. | Q35956610 | ||
| Second-generation antipsychotic medications in children and adolescents | Q36009445 | ||
| Psychiatric and medical comorbidities of bipolar disorder | Q36021272 | ||
| Medical comorbidity and health-related quality of life in bipolar disorder across the adult age span. | Q36093549 | ||
| Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications | Q36216515 | ||
| Metabolic side effects of atypical antipsychotics in children: a literature review | Q36258561 | ||
| Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents | Q36328308 | ||
| The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. | Q36349761 | ||
| Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents | Q36532942 | ||
| Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials | Q36639919 | ||
| Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials | Q36827082 | ||
| Abnormal involuntary movements in neuroleptic-naive children and adolescents | Q41665850 | ||
| The health care crisis of childhood-onset bipolar illness: some recommendations for its amelioration. | Q42678459 | ||
| The association between childhood depression and adulthood body mass index | Q43594544 | ||
| Prevalence of obesity and weight change during treatment in patients with bipolar I disorder | Q43642752 | ||
| Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study | Q43789283 | ||
| A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder | Q43966075 | ||
| Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. | Q43997748 | ||
| Fluoxetine and extrapyramidal side effects | Q44348223 | ||
| Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: a case report | Q44528640 | ||
| The poor prognosis of childhood-onset bipolar disorder | Q44620166 | ||
| Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions | Q44634738 | ||
| A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial | Q44635621 | ||
| Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey | Q44986547 | ||
| Burden of general medical conditions among individuals with bipolar disorder | Q45070754 | ||
| Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians | Q46714706 | ||
| Clinical features of bipolar disorder with and without comorbid diabetes mellitus | Q47629610 | ||
| Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. | Q51785668 | ||
| National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. | Q51941986 | ||
| Incidence and Duration of Side Effects and Those Rated as Bothersome With Selective Serotonin Reuptake Inhibitor Treatment for Depression | Q55890546 | ||
| P433 | issue | 7 | |
| P921 | main subject | bipolar disorder | Q131755 |
| teenager | Q1492760 | ||
| P304 | page(s) | 451-459 | |
| P577 | publication date | 2011-09-07 | |
| P1433 | published in | Human Psychopharmacology | Q15751477 |
| P1476 | title | Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. | |
| P478 | volume | 26 |
| Q90305536 | Association of mood disorders with cardiovascular disease risk factors in overweight and obese youth with elevated blood pressure |
| Q47101588 | Bipolar Spectrum Disorders in Male Youth: The Interplay between Symptom Severity, Inflammation, Steroid Secretion, and Body Composition |
| Q39225001 | Depression, its comorbidities and treatment, and childhood body mass index trajectories |
| Q49348752 | Efficacy and Safety Profile of Risperidone Long-acting Injection in Adolescents in a Real-life Setting |
| Q38160202 | Obesity and bipolar disorder: synergistic neurotoxic effects? |
| Q27027052 | Pharmacotherapy of bipolar disorder in children and adolescents: an update |
| Q26752530 | Significantly Higher Prevalence Rate of Asthma and Bipolar Disorder Co-Morbidity: A Meta-Analysis and Review Under PRISMA Guidelines |
Search more.